Search
                    Alzheimer's Disease Clinical Trials
A listing of 28  Alzheimer's Disease  clinical trials  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1 - 12 of 28
        
                There are currently 28 active clinical trials seeking participants for Alzheimer's Disease research studies. The states with the highest number of trials for Alzheimer's Disease participants are Florida, California, New York and Arizona.
            
                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    
                
                                    Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
                                
            
            
        Recruiting
                            
            
                The study is designed to characterize the clinical, neuropsychological, polysomnographic, and neuroimaging findings among subjects with Alzheimer's disease, Lewy Body dementia, and Parkinsons' Disease.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                03/25/2025
            
            Locations: The Ohio State University, Columbus, Ohio         
        
        
            Conditions: Alzheimer's Disease, Lewy Body Dementia, Parkinson's Disease
        
            
        
    
                
                                    A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease             
        
        
    Gender:
                ALL
            Ages:
                Between 60 years and 85 years
            Trial Updated:
                08/19/2025
            
            Locations: Local Institution - 0173, Long Beach, California  +111 locations         
        
        
            Conditions: Alzheimer's Disease
        
            
        
    
                
                                    A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease             
        
        
    Gender:
                ALL
            Ages:
                Between 60 years and 85 years
            Trial Updated:
                08/15/2025
            
            Locations: Fullerton Neurology and Headache Center, Fullerton, California  +115 locations         
        
        
            Conditions: Alzheimer's Disease
        
            
        
    
                
                                    Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease
                                
            
            
        Recruiting
                            
            
                This study consists of 2 parts, Part A and Part B. Part A is a single center, randomized, double-blind, placebo-controlled cohort designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of NMRA-323511 among healthy elderly.
Part B is a multicenter, randomized, double-blinded, placebo-controlled, parallel-group cohort to evaluate the safety, tolerability, and efficacy of NMRA-323511 among adults with Agitation Associated with Dementia due to Alzheimer's Disease.
Part A consists...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 55 years and 90 years
            Trial Updated:
                08/08/2025
            
            Locations: Neumora Investigator Site, Chandler, Arizona  +24 locations         
        
        
            Conditions: Alzheimer's Disease, Healthy Elderly
        
            
        
    
                
                                    TREAD: Time Restricted Eating Intervention for Alzheimer's Disease
                                
            
            
        Recruiting
                            
            
                The goal of this clinical trial is to learn if restricting the time of eating to allow for prolonged fasting at night may reduce sleep disturbances, cognitive decay, and pathology in patients diagnosed with Mild Cognitive Impairment (MCI) or early to moderate Alzheimer's disease (AD). It will also learn about the feasibility of practicing 14 h of nightly fasting in this group of older adults. The main questions it aims to answer are:
* Does prolonged nightly fasting of 14 h can reduce markers o...  Read More             
        
        
    Gender:
                ALL
            Ages:
                60 years and above
            Trial Updated:
                08/03/2025
            
            Locations: Shiley Marcos Alzheimer's Disease Center, San Diego, California         
        
        
            Conditions: Mild Cognitive Impairment, Alzheimer Disease, Alzheimer's Disease
        
            
        
    
                
                                    A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo.
Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participat...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 55 years and 80 years
            Trial Updated:
                07/30/2025
            
            Locations: Parkway Medical Center, Birmingham, Alabama  +278 locations         
        
        
            Conditions: Alzheimer's Disease
        
            
        
    
                
                                    DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
                                
            
            
        Recruiting
                            
            
                This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU-001 gantenerumab Open Label Extension (OLE) period with lecanemab to determine the effects of amyloid removal on age of onset and clinical progression compared to external controls, if amyloid plaque as measured by amyloid PET can be fully removed in DIAD, and the effects of amyloid removal on biomarkers of disease progression.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/30/2025
            
            Locations: University of Alabama in Birmingham, Birmingham, Alabama  +5 locations         
        
        
            
        
    
                
                                    Wake Forest Alzheimer's Disease Clinical Core
                                
            
            
        Recruiting
                            
            
                Efforts to find treatments for AD have yielded only modest benefits, likely because longstanding AD pathological processes induce irreversible neurological compromise. These processes begin years before the onset of clinical symptoms. This possibility has been incorporated into a model describing stages of AD development, articulated by the NIA/Alzheimer's Association preclinical workgroup of which the Co-Director of the Kulynych Alzheimer's Research Center, Dr. Suzanne Craft, was a member. Acco...  Read More             
        
        
    Gender:
                ALL
            Ages:
                55 years and above
            Trial Updated:
                07/25/2025
            
            Locations: Wake Forest Baptist Health, Winston-Salem, North Carolina         
        
        
            Conditions: Alzheimer's Disease, Mild Cognitive Impairment, Prediabetic State
        
            
        
    
                
                                    A Multi-Modal Combination Intervention to Promote Cognitive Function in Older Intensive Care Unit Survivors
                                
            
            
        Recruiting
                            
            
                Up to 25% of intensive care unit (ICU) survivors experience cognitive impairment comparable in severity to mild Alzheimer's disease and related dementias after hospital discharge. Older ICU survivors (ages 60 and older) are at highest risk for delirium and subsequent cognitive impairment, which contribute to higher risk for cognitive decline related to Alzheimer's disease and related dementias. Sleep and activity are essential for recovery from critical illness, yet ICU survivors experience both...  Read More             
        
        
    Gender:
                ALL
            Ages:
                60 years and above
            Trial Updated:
                07/16/2025
            
            Locations: University of Washington, Seattle, Washington         
        
        
            Conditions: Critical Illness, Delirium, Cognitive Impairment, Cognitive Decline, Alzheimer's Disease, Dementia, Circadian Dysrhythmia, Sleep Disturbance
        
            
        
    
                
                                    Dominantly Inherited Alzheimer Network (DIAN)
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/14/2025
            
            Locations: Mayo Clinic Jacksonville, Jacksonville, Florida  +24 locations         
        
        
            Conditions: Alzheimer's Disease
        
            
        
    
                
                                    Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
                                
            
            
        Recruiting
                            
            
                Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective. Digital biomarkers and blood-based biomarkers will be tested to determine whether a meaningful relationship exists between biomarkers alone or in combination with tau or amyloid brain pathology identified through PET images.             
        
        
    Gender:
                ALL
            Ages:
                Between 60 years and 90 years
            Trial Updated:
                07/11/2025
            
            Locations: JEM Research Institute, Atlantis, Florida  +22 locations         
        
        
            Conditions: Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss, Memory Disorders, Memory Impairment
        
            
        
    
                
                                    Alzheimer's Prevention Registry: A Program to Accelerate Enrollment Into Studies
                                
            
            
        Recruiting
                            
            
                The Alzheimer's Prevention Registry (www.endALZnow.org) will collect contact and demographic information on individuals. The objective is to provide information the latest news and advances in Alzheimer's prevention research, and to inform enrollees about research studies in their community. Enrolled individuals will receive regular email communications. As research studies become available, individuals will be notified via email with information as to how proceed should they be interested. Regi...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 110 years
            Trial Updated:
                06/27/2025
            
            Locations: Banner Alzheimer's Institute, Phoenix, Arizona         
        
        
            Conditions: Alzheimer's Disease, Dementia
        
            
        
    1 - 12 of 28
            